Healthcare: Devices

Swaasa: Artificial intelligence platform as a screening tool and diagnostic aid in the assessment of respiratory diseases

APPLICATION

Swaasa can identify underlying respiratory lung conditions by analyzing a 10 second (solicited) cough sound recording. Swaasa can be thought of as PoC SaMD for instant evaluation of respiratory health. The equivalent of home monitoring for Blood Glucose and Blood Pressure-for respiratory health

COMPANY NAME

Salcit Technologies Pvt Ltd

FOUNDER'S NAME

Narayan Rao Sripada

TECHNOLOGY READINESS LEVEL (TRL)

TRL: **8** (Early Revenue Generation Phase)

INTELLECTUAL PROPERTY

PCT: WO2019116381 NP in US20230263141A1

Canada: 3083639 (Granted)

Indian Patent No. 308156

PROBLEM ADDRESSED

Screening for respiratory diseases is an unmet need as due to limited human expertise and lab facilities, it is not possible to do pulmonary function tests at primary care level centres. The inability to **screen**, **diagnose** and **monitor** lung health at scale, in real-time is causing significant global burden on respiratory diseases

ABOUT THE TECHNOLOGY

Ourproduct, Swaasa, is able to detect respiratory diseases by analyzing cough sounds *remotely*. Over 300,000 assessments have been done on our platform. Swaasa is HIPAA, ISO27001, SOC2, ISO13485/IEC62304 compliant/certified. Backed by seven clinical trials we are on the path to regulatory approvals (FDA/CE/HealthCanada/TGA). The core technology also has international patents and publications. Swaasa is the ideal tool to selftest/monitor for lung health anywhere, anytime especially since it is a **SaMD** (Software as a Medical Device) so no hardware needed. Using timely alerts and interventions can be a powerful tool for preventing acute episodes of chronic lung conditions.

FUNDS RAISED/ACHIEVEMENTS

- Received ISO and IEC Certifications for the product
- SASACT fund of INR 24 lakhs from KIIT TBI
- BIRAC BIG grant of INR 50 lakhs

PRODUCT IMAGE



USP

The Swaasa AI platform provides easy and cost-effective tests to reach larger populations at a much higher frequency of testing.
The platform:

- Does not require trained professionals
- Does not require any specific hardware-can work on smartphone, tablet or laptop
- No other consumables needed
- Requires very low-bandwidth

END USERS/CUSTOMERS

- B2B –Enterprise health service providers, tele and home health service providers, Occupational health service providers
- B2G –Public health

Dr. Amaresh Panda
Lead, Technology Transfer Office, KIIT-TBI
amaresh@kiitincubator.in| +91-9819053408

Dr. Samuel Rout
Manager, Technology Transfer Office, KIIT-TBI
samuel@kiitincubator.in| +91-7735389456

tto@kiitincubator.in | tto.kiitincubator.in